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Congenital malformations are the major cause of infant mortality in the US and Europe. Due to rapid
advances in human genomics, we can now efﬁciently identify sequence variants that may cause disease
in these patients. However, establishing disease causality remains a challenge. Additionally, in the case of
congenital heart disease, many of the identiﬁed candidate genes are either novel to embryonic devel-
opment or have no known function. Therefore, there is a pressing need to develop inexpensive and
efﬁcient technologies to screen these candidate genes for disease phenocopy in model systems and to
perform functional studies to uncover their role in development. For this purpose, we sought to test F0
CRISPR based gene editing as a loss of function strategy for disease phenocopy in the frog model or-
ganism, Xenopus tropicalis. We demonstrate that the CRISPR/Cas9 system can efﬁciently modify both
alleles in the F0 generation within a few hours post fertilization, recapitulating even early disease
phenotypes that are highly similar to knockdowns from morpholino oligos (MOs) in nearly all cases
tested. We ﬁnd that injecting Cas9 protein is dramatically more efﬁcacious and less toxic than cas9
mRNA. We conclude that CRISPR based F0 gene modiﬁcation in X. tropicalis is efﬁcient and cost effective
and readily recapitulates disease and MO phenotypes.
& 2015 Elsevier Inc. All rights reserved.1. Introduction
Congenital malformations are a major cause of morbidity and
mortality in infants and children. Of the congenital malformations,
congenital heart disease (CHD) is the most common (Dolk et al.,
2011; Pediatric Cardiac Genomics et al., 2013; van der Linde et al.,
2011). Despite the enormous impact CHD has on child health, our
understanding of the causes of CHD remains rudimentary. Re-
cently, a number of studies have employed human genomics to
identify over 350 candidate genes that may cause CHD (Fakhro
et al., 2011; Glessner et al., 2014; Greenway et al., 2009; Hitz et al.,
2012; Priest et al., 2012; Warburton et al., 2014; Zaidi et al., 2013;
Zhao et al., 2013). However, due to high locus heterogeneity and
lack of second alleles, the disease relevance of the vast majority of
these gene variants is uncertain. In addition, many of the genes
identiﬁed are either novel to cardiac development, novel to em-
bryonic development, or have no known function (Fakhro et al.,
2011; Glessner et al., 2014; Greenway et al., 2009; Zaidi et al.,
2013). Functionally testing these CHD candidate genes for ahokha).developmental role would improve our understanding of the
genes that pattern the heart and the early embryo. Subsequent
studies could then explore their developmental mechanisms.
Therefore, given the large number of CHD candidate genes, there is
a pressing need for a rapid and inexpensive loss of function
strategy to test candidate disease genes for phenocopy in model
systems.
Xenopus is an ideal model for studying human embryonic de-
velopment. Compared to mammalian systems, Xenopus is rapid
and cost effective, which is essential in order to evaluate the large
number of genes emerging from human genomics studies of birth
defect patients. In addition, Xenopus have a three-chambered heart
with a highly trabeculated myocardium and a partially septated
atria. The evolutionary conservation between Xenopus and hu-
mans offers additional opportunities to model human disease
compared to other high-throughput aquatic vertebrates.
Traditionally, knockdown in Xenopus is achieved using trans-
lation or splice-site blocking morpholino oligos (MOs). MOs can
target maternal and zygotic transcripts in order to achieve sub-
stantial or partial knockdown in F0 embryos (i.e. embryos that are
injected with the MO). However, there are some disadvantages.
MOs cost $400 per oligo and can become prohibitively expensive
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now for CHD. Also, in zebraﬁsh, the speciﬁcity of MOs has recently
been challenged (Kok et al., 2015). Unfortunately, it can be difﬁcult
to assess the off-target effects of MOs, and with start site MOs,
efﬁcacy of knockdown cannot be examined without an effective
antibody. Therefore, correlating phenotype with knockdown can
be challenging.
Recently, a number of genome editing tools have dramatically
transformed our ability to generate mutations in the genome. Of
these, clustered regularly inter-spaced short palindromic repeats
(CRISPRs) are truly revolutionizing gene-editing technology in al-
most every model organism including Xenopus (Bassett and Liu,
2014; Blitz et al., 2013; Friedland et al., 2013; Guo et al., 2014;
Hwang et al., 2013; Li et al., 2013; Nakayama et al., 2013; Wang
et al., 2014). Due to its high efﬁcacy and simplicity, CRISPR based
gene editing appears amenable for large-scale genome screening.
In the CRISPR/ Cas9 system, a site-speciﬁc small guide RNA
(sgRNA) targets the genomic sequence adjacent to a PAM se-
quence, “NGG”, and recruits the Cas9 endonuclease to create a
double stranded break. This is then repaired by non-homologous
end joining, leading to insertions and deletions that can cause a
frame shift, often leading to a null allele. In zebraﬁsh and Xenopus,
cas9 mRNA is commonly co-injected with the target sgRNA to
induce gene modiﬁcations using CRISPRs. However, three recent
papers in zebraﬁsh suggest that injecting Cas9 protein is faster and
yields more mutagenesis than injecting cas9 mRNA (Gagnon et al.,
2014; Kotani et al., 2015; Sung et al., 2014). The use of Cas9 protein
remains unexplored in Xenopus.
In this study, we sought to determine if CRISPR based gene
editing could recapitulate disease phenotypes in F0 Xenopus em-
bryos. While previous work in Xenopus has shown that F0 gene
modiﬁcations occur in at least eleven different genes, these studies
combined examined embryonic phenotypes for only three loci in
F0 animals (tyrosinase, six3, ptf1a/p48) (Blitz et al., 2013; Guo et al.,
2014; Nakayama et al., 2013). In each case, phenotypes were de-
tected at stage 40 or later in development, which is roughly three
days after fertilization. However, the patterning events that
lead to many disease and developmental phenotypes, including
cardiac development, occur much earlier. In addition, the devel-
opment of Xenopus is rapid, and further, our diploid model Xeno-
pus tropicalis thrives at warmer temperatures, making its devel-
opment even more rapid than Xenopus laevis. Therefore, we
wondered if CRISPR/Cas9 could modify the genome rapidly en-
ough to affect early developmental events in F0 embryos and re-
capitulate those disease phenotypes seen in birth defects patients,
including CHD.
In this study, we use the CRISPR/Cas9 system to test six human
disease genes (galnt11, dnah9, ccdc40, foxj1, pax8, and beta-catenin)
with diverse phenotypes and compare them to established MO or
mutant phenotypes. Given the importance of ciliopathies in hu-
man disease including CHD, we chose four genes (galnt11, dnah9,
ccdc40, and foxj1) that affect cilia in different ways, and conse-
quently have different mechanisms to affect cardiac development
(Brueckner, 2007; Li et al., 2015; Sutherland and Ware, 2009). In
each case, these genes affect development by acting at stages 16-
19 (within 20 h of development). To examine organogenesis in an
organ system that has yet to be tested using CRISPR, we examined
kidney development with pax8, which also plays a critical role as
early as stage 18, or 15 h of development. Finally, to test the lim-
itations of the technology, we examined beta-catenin, which has a
known maternal role that can be effectively targeted with a
translation blocking MO to create a ventralized phenotype
(Heasman et al., 1994, 2000; Wylie et al., 1996). We demonstrate
that F0 CRISPR analysis is a powerful and dramatically less ex-
pensive loss of function screening tool than MOs. It readily re-
capitulates disease phenotypes that are nearly identical to MOs inmost cases tested. Cas9 protein creates gene modiﬁcations
more rapidly and effectively than cas9 mRNA with dramatically
less toxicity, enabling the detection of early embryonic
phenotypes. We conclude that F0 CRISPR is an efﬁcient screening
tool for testing congenital malformation candidate genes in
Xenopus.2. Results
2.1. Fragment Analysis (FA) is a rapid and efﬁcient way to detect
gene modiﬁcation
During a screen for gene function via genome modiﬁcation
using CRISPR/Cas9, there are two possible outcomes: (1) we detect
a phenotype, in which case we want to conﬁrm that gene mod-
iﬁcation of the targeted site correlates with the phenotype; (2) we
fail to detect a phenotype, in which case, we want to conﬁrm that
there is evidence for gene modiﬁcations at the target site and that
those gene modiﬁcations are such that they would be deleterious
(i.e. not 3 base pair deletions). If no such modiﬁcation is found, we
can target the loci with another sgRNA and if there is still no
phenotype, we can conclude the screen of that gene. To begin our
studies, we ﬁrst sought to adapt a simple assay to test the efﬁcacy
of CRISPR mediated genome modiﬁcation in Xenopus. Previous
work has employed PCR ampliﬁcation of the modiﬁed locus and
either (1) direct sequencing of the PCR amplicons or (2) cloning of
the PCR products followed by sequencing. The ﬁrst method is
limited by mosaicism, which scrambles the sequence traces mak-
ing it difﬁcult to determine the size and type of mutation (inser-
tion/deletion) (Blitz et al., 2013; Nakayama et al., 2013). The sec-
ond method is more time consuming due to multiple cloning steps
and samples a relatively small number of PCR products. For
screening purposes, the most critical information is the size of the
indel, since early frameshift mutations are most likely to cause a
loss of function allele. Additionally, an inexpensive and rapid
method to genotype embryos would be powerful to correlate
novel phenotypes with expected deleterious genotypes. Fragment
Analysis (FA), where PCR products are run on a standard capillary
gel in order to determine product size at single base pair resolu-
tion, can provide this information inexpensively and efﬁciently
(Schuelke, 2000; Yang et al., 2015).
We began our studies with the tyrosinase (tyr) locus and used
FA to test CRISPR efﬁciency. We employed the same sgRNA and
PCR amplicon in previous studies (Blitz et al., 2013; Nakayama
et al., 2013), a 261 base-pair (bp) product that is easily resolved
using FA (Fig. 1(c)). When we inject embryos at the one cell stage
with cas9 mRNAþtyr sgRNA, and then assay their genotype by FA,
we observe a characteristic 4 bp deletion peak. In Xenopus, if only
1 cell at the 2-cell stage is injected, we can select embryos tar-
geting only one side of the embryo. In this case, FA reveals both the
Wild Type (WT) and the 4 bp deletion alleles. Interestingly, if we
substitute Cas9 protein for mRNA, we ﬁnd additional peaks cor-
responding to an 8 bp deletion, as well as some insertions. These
additional peaks were very rarely observed when the embryos
were injected with cas9 mRNA (Supp. Fig. S1).
When we clone and sequence these PCR products, we ﬁnd two,
three, four, and eight bp deletions in the target region. The ma-
jority of the clones (58%) show 4 or 8 bp deletions and the pro-
portion of these colonies roughly correlate with the height of the
peaks on FA. Although sometimes an array of peaks are observed,
each sgRNA seems to have a characteristic deletion peak which is
shared in all injected embryos. For example, all embryos injected
with our tyrosinase sgRNA have a characteristic 4 bp deletion peak,
while most of those injected with galnt11 sgRNA have a 10 bp
deletion peak, dnah9 sgRNA embryos have a 11 bp deletion peak,
D. Bhattacharya et al. / Developmental Biology 408 (2015) 196–204198ccdc40 sgRNA embryos have a 16 bp deletion peak, and pax8
sgRNA embryos have a 17 bp deletion peak (Supp. Fig. S3(a)–(e)).
Furthermore, the same deletion peaks are detected in the DNA ofadult frogs previously injected with Cas9 and sgRNA. Therefore,
these deletions are stable and detectable over time, and FA can
serve as a rapid and inexpensive F0 genotyping assay.
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In all Xenopus reports to date, cas9 mRNA is co-injected with
the target sgRNA to induce gene modiﬁcations using CRISPRs (Blitz
et al., 2013; Guo et al., 2014; Nakayama et al., 2013, 2014; Wang
et al., 2015). In Xenopus, we must inject 2–4 ng/embryo of cas9
mRNA to generate an F0 phenotype at the tyrosinase locus (al-
binism). However, cas9 mRNA at a dose of 2 ng/embryo is fairly
toxic leading to 450% death in embryos (Supp. Fig. S2). In addi-
tion, a substantial percentage of surviving embryos are malformed
which is not expected if mutations were restricted to the tyr locus.
A similar degree of toxicity has been reported in a previous study
(Guo et al., 2014). This toxicity is dose dependent, where more
embryos survive at lower doses. However, injecting lower doses of
cas9mRNA dramatically reduces the incidence of F0 phenotypes. If
we instead inject Cas9 protein directly into the embryo, we ob-
serve no toxic effects above uninjected controls, with close to 90%
of embryos surviving. Furthermore, the degree of albinism is much
more pronounced with Cas9 protein co-injection compared to cas9
mRNA (Fig. 1(c), Supp. Fig. S2).
2.3. Cas9 gene modiﬁcations occur early in development
Next, in order to recover F0 phenotypes, especially phenotypes
that occur early in development, the timing of the CRISPR/Cas9
mediated gene modiﬁcations is important. Once cas9 mRNA is
injected, it needs to be translated, the protein folded, and the Cas9/
sgRNA complex assembled before genome editing can occur. We
would expect this process to occur more rapidly if Cas9
protein was injected, especially if the Cas9 protein was incubated
with the sgRNA prior to injection, although the kinetics of this
process is not clear. Two studies in zebraﬁsh suggest that injecting
Cas9 protein induces mutations faster than cas9 mRNA (Kotani
et al., 2015; Sung et al., 2014). Since Xenopus development is
rapid, slow kinetics could preclude detecting early phenotypes
in F0 animals. Clearly, phenotypes at later stages, such as albinism
at stage 40, can be detected, but whether F0 phenotypes can be
detected in Xenopus at earlier stages, such as stage 20, is not
known.
Therefore, we sought to determine the timing of deletions after
injecting Cas9þsgRNA. To test this, we performed a time course
experiment by injecting cas9 mRNA or protein with the tyrosinase
sgRNA at the one cell stage, and collected embryos every 2 h post-
injection. We used FA to assay for the presence of deletions. Im-
portantly, even as early as two hours post-injection, deletions
were detected in 50% of embryos injected with cas9 mRNA and
100% of embryos injected with Cas9 protein. With time, a greater
percentage of embryos had deletions, and we note that at stage 9
(5 h post-fertilization), when the maternal to zygotic transition
(MZT) occurs, embryos co-injected with Cas9 protein/sgRNA had
more evidence of biallelic modiﬁcations than embryos co-injected
with cas9 mRNA. At every time point, a greater percentage of
embryos had deletions with Cas9 protein compared to cas9mRNAFig. 1. Strategy for custom sgRNA design, Fragment Analysis, and study of tyrosinase CR
with the red box outlining the forward primer for any target gene of interest. *This strate
sequence and use of Ambion's MegaShortscript kit, which greatly increases RNA yield
promoter (yellow), 18 bp target sequence (green), and 20 bp complimentary overhang wi
overhang (black) and the remaining sgRNA sequence (blue). With one PCR step we genera
which is co-injected with cas9mRNA or protein. (b) Strategy for fragment analysis. Forwa
the target locus. A 2nd PCR step with a ﬂorescent m13 Primer and the same R-primer ar
electrophoresis gel and analyzed. (c) Stage 42 embryos and their FA genotype (dorsal vie
axis ¼ relative intensity of PCR signal to loading control. WT tadpole and the correspo
sgRNA and corresponding 257 bp FA peak (4 bp deletion). GFP co-expression is observed
on left side (GFP co-expression only on left) and both deletion and WT peaks detected w
deletion peak on FA.(po0.05 at all time points) (Fig. 2). These results also correlate
with the greater degree of albinism seen in Cas9 protein vs. mRNA-
injected embryos. Taken together, we conclude that Cas9 protein is
less toxic and more efﬁcacious than cas9 mRNA, and can poten-
tially target genes that are expressed at the onset of MZT. For all
subsequent experiments we injected Cas9 proteinþsgRNA, which
we abbreviate as CRISPRp.
2.4. CRISPRp injected embryos phenocopy established mutant or MO
knockdown phenotypes in the F0 generation
We next wanted to test if F0 CRISPR mediated gene deletion
could recapitulate known mutant or MO knockdown phenotypes.
We sought to examine disease-causing genes that create a diverse
array of disease phenotypes, including ciliopathies that can cause
CHD and heterotaxy (foxj1, ccdc40, dnah9, galnt11) and an organ
system (kidneys) that has not yet been targeted in Xenopus (pax8).
In each case, these genes affect development well before stage 20,
providing a test of how early CRISPRp can affect development as
well as a diversity of phenotypes.
First we looked at a range of ciliopathy genes. We chose this set
of genes for the diversity of ciliopathies; in some cases, loss of
function leads to less ciliated cells (ccdc40, foxj1), more ciliated
cells (galnt11), or normal cilia morphology but reduced motility
(dnah9). Foxj1 MO knockdown leads to decreased epidermal cilia
(Stubbs et al., 2008) and 68% of our foxj1 CRISPRp injected em-
bryos (n¼38) had grossly reduced epidermal ciliated cells (Fig. 3,
Table 1). The endogenous FoxJ1 protein levels, as assayed by
western blot were decreased in both MO and CRISPR injected
embryos (Supp. Fig. S3(f)). Similarly, ccdc40 mutations cause pri-
mary ciliary dyskinesia that leads to decreased and abnormal cilia
in patients and in Xenopus (Becker-Heck et al., 2011; del Viso et al.,
2012). Injecting ccdc40 CRISPRp readily recapitulated this de-
creased and abnormal cilia phenotype in 48% of injected embryos
(n¼40), and these embryos had a corresponding 16 bp deletion
peak (Supp. Fig. S3(c) and (g), Table 1).
Next, we looked at two genes, dnah9 and galnt11, that both
affect left–right patterning of the developing embryo and cardiac
development (Boskovski et al., 2013; Vick et al., 2009). Dnah9 is an
important component of the ciliary axoneme that affects cilia
motility, but not ciliogenesis, and causes laterality defects when
knocked down (Vick et al., 2009). 28% of dnah9 CRISPRp injected
embryos (n¼32) had heart-looping defects (A or L loops) and all of
these embryos contained a characteristic 11 bp deletion peak
(Table 1, Supp. Fig. S3(b)). Furthermore, as expected, the injected
embryos had normal epidermal cilia staining (Supp. Fig. S3(g)).
Galnt11, on the other hand, is a Notch regulator identiﬁed from a
patient with heterotaxy, and its loss leads to a left–right patterning
defect as well as an increase in multiciliated epidermal cell density
(Boskovski et al., 2013; Fakhro et al., 2011). 23% of our galnt11
CRISPRp injected embryos (n¼35) had A and L heart looping de-
fects, which is comparable to the 25% heart looping defects ob-
served with MO knockdown (Boskovski et al., 2013). 50% of theseISPR phenotype and genotype. (a) Strategy for custom sgRNA design (PCR method)
gy was modiﬁed from that described by Nakayama et al. by addition of 5 bp anchor
(see Section 4). The forward primer consists of 5 bp anchor sequence (red), T7
th reverse primer (black). The stock reverse primer consists of 20 bp complementary
te the full sgRNA template. We then use in vitro transcription to generate the sgRNA
rd primer with a 5′-m13 overhang sequence is used with a R-primer to PCR amplify
e used to generate a ﬂuorescently tagged PCR amplicon, which is run on a capillary
w, anterior to the left). FA genotype – X-axis ¼ size of amplicon in basepairs (bp), Y-
nding 261 bp PCR amplicon; Tadpole injected at 1-cell stage with cas9 mRNAþtyr
in whole embryo; tadpole injected at 1-of-2-cell stage with cas9 mRNAþtyr sgRNA
ith FA; tadpole injected with Cas9 protein and tyr sgRNA at 1-cell stage with 257 bp
Fig. 2. Time course of CRISPR/Cas9 deletions. All embryos injected with tyr sgRNA and either injected with cas9 mRNA or Cas9 protein. X-axis¼time/stage of embryos post-
injection (number of embryos in parenthesis). Y-axis¼%embryos with corresponding FA genotype (blue¼WT allele only, green¼both alleles detected, red¼mutant allele
only). Statistical analysis performed by Fisher exact probability test, *¼po0.05.
Fig. 3. CRISPR injected embryos phenocopy established mutant or MO knockdown phenotypes in the F0 generation. Left panel¼WT embryo, middle panel¼MO injected
embryo, right panel¼CRISPRp injected embryo. (a) Foxj1 CRISPRp – immunohistochemistry of stage 28 embryos with acetylated tubulin to mark surface cilia. (b) Pax8
CRISPRp – in situ hybridization of stage 38 embryos with pax2 probe to stain kidney tubule. Black arrow points to pronephros.
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crease in epidermal ciliated cell density, and all injected embryos
contained a characteristic 10 bp deletion peak when analyzed by
FA (Table 1, Supp. Fig. S3(a) and (g)).
Next, to examine kidney development, we tested pax8, a tran-
scription factor critical for the speciﬁcation of the pronephros and
proper kidney development. MO knockdown as well as the pre-
viously published pax8mutant, Ruby (del Viso et al., 2012), leads to
abnormal pronephros development as assayed by pax2 in situhybridization. 40% of pax8 CRISPRp injected embryos (n¼47)
showed abnormal pronephros development, and we detected a
17 bp deletion peak in these injected embryos by FA (Fig. 3, Supp.
Fig. S3(e), Table 1).
Finally, we designed a CRISPR to beta-catenin, a maternally
expressed gene, which, when knocked down using a translation
blocking MO, leads to a severe ventralization of the embryos
(Heasman et al., 2000; Khokha et al., 2002; Khokha et al., 2005).
However, in CRISPRp injected embryos we do not observe gross
Table 1.
Summary of genes and CRISPR phenotypes.
Gene/mutation OMIM disease phenotype Morpholino/mutant line phenotype CRISPR phenotype (% of embryos)
FoxJ1 Allergic rhinitis, Autoimmune
disease
90% Decreased epidermal cilia (Stubbs et al., 2008) 68% decreased epidermal cilia
Ccdc40 Primary ciliary dyskinesia Decreased and abnormal epidermal cilia (Becker-Heck et al., 2011; del
Viso et al., 2012)
48% decreased and abnormal epidermal
cilia
Dnah9 Primary ciliary dyskinesia 30% laterality defect (Vick et al., 2009) 28% AþL heart loops
Galnt11 Heterotaxy 25% AþL heart loops; Increased Epidermal Cilia (Boskovski et al.,
2013)
23% AþL heart loops; 50% increased
Epidermal Cilia
Pax8 Kidney agenesis, Hypothyroidism 59% Malformed pronephros (del Viso et al., 2012) 40% malformed pronephros
Tyrosinase Oculocutaneous albinism Albinism (Blitz et al., 2013; Guo et al., 2014; Nakayama et al., 2013) 100% Albinism
Beta-catenin Cancer, intellectual disability Ventralization of embryo (Heasman et al., 2000; Khokha et al., 2002) No ventralization
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array of deletions on FA (Supp. Fig. 3(d)).3. Discussion
Here, we show that the CRISPR/ Cas9 system can identify F0
phenotypes for human disease genes and has a number of ad-
vantages. First, FA is an efﬁcient strategy to detect deletions and
insertions in most genes. Second, Cas9 protein is less toxic and
more efﬁcient in creating gene modiﬁcations than cas9 mRNA.
Additionally, with Cas9 protein, there is a high degree of biallelic
gene modiﬁcation by the MZT, allowing for the study of early zy-
gotic gene function in F0 embryos. Third, CRISPRp injected em-
bryos recapitulate a diverse array of mutant or MO knockdown
phenotypes in the F0 generation, and these embryos can be ana-
lyzed using standard molecular techniques like in situ hybridiza-
tion, immunohistochemistry, and western blotting, similar to MO
injected animals.
Furthermore, unlike MOs, it is simple to assay the efﬁcacy of
CRISPR mediated gene disruption by PCR. In this paper, we employ
FA to distinguish wildtype alleles from deletions or insertions at a
single base-pair resolution. This method is also inexpensive – at
Yale, it costs $0.50 to run one lane of FA and with four ﬂurophores
commercially available, one can run up to four samples per lane
reducing the cost to $0.13 per sample. FA can also be done in a 96-
well plate format allowing for quick analysis of multiple embryos
and targets. However, our PCR conditions are not amenable to
quantitation, so peaks seen on FA only correlate with the per-
centage of clones or cells that contain that deletion or insertion. In
using FA, we were surprised to detect characteristic single deletion
peaks in most embryos injected with a particular sgRNA. Cloning
these PCR products indicates that while many deletions are of the
same size and occur in a similar region of the target sequence, only
some of them are identical. This suggests that there are in-
dependent double strand break and repairs in multiple cells dur-
ing early cell division, after which those cells give rise to a clonal
population of cells all with the same deletion. From our time-
course, we conclude that deletions are detectable as early as 2 h
post-injection and they are detected in a greater percentage of
embryos when injected with Cas9 protein compared to mRNA.
This builds conﬁdence that studying early developmental events
might be tractable using this technology, especially if Cas9 protein
is used.
Finally, we show that the CRISPR/Cas9 system can be used to
phenocopy known mutant and MO knockdown phenotypes in a
variety of genes affecting heart development, ciliogenesis or kid-
ney development. These phenotypes are characteristic since foxj1
and ccdc40 CRISPRp decrease the number of epidermal cilia, dnah9
CRISPRp affects heart looping, but does not affect the number ofepidermal cilia, while galnt11 CRISPRp causes heart looping de-
fects and increases the number of epidermal ciliated cells. Al-
though mosaic, we can successfully generate biallelic deletions in
the F0 generation, and these embryos can be studied using stan-
dard molecular techniques like in situ hybridization, im-
munohistochemistry, and western blotting.
We do note that penetrance of the phenotype does not always
correlate with the genotype detected by FA. On one hand, this is
reﬂective of the penetrance of the phenotypes that we studied. For
example, mouse null mutants of many heterotaxy genes show
abnormal cardiac looping in only 50% of embryos (Li et al., 2015;
Supp et al., 1997). Also because our overall goal was to test the
viability of CRISPRp for a large scale screen of many birth defect
genes, in cases where patches of cells with an abnormal pheno-
type were present but a dramatic or more generalized phenotype
was absent, the embryos were scored as wildtype. These more
subtle phenotypes can be difﬁcult to detect when screening many
genes, especially when the phenotype is unknown. Importantly,
even with this “high bar,” phenotypes were detected in substantial
percentages of embryos over controls, reassuring us that CRISPRp
can be highly effective for large scale F0 loss of function screens.
While F0 CRISPR based gene editing has many advantages,
challenges remain, and there are limitations to using CRISPR
technology. First, it is essential to determine if a particular sgRNA
favors indels that cause a frameshift. Second, different sgRNAs can
have different DNA editing efﬁciency and further studies need to
establish factors that determine sgRNA activity and efﬁciency.
Third, the ability to design and use CRISPRs effectively depends
upon the quality of the genome models for a particular organism.
For example, the Xenopus genome models are not polished to the
degree of human or rodent genomes and some genes are still not
properly annotated. We initially designed an sgRNA to the anno-
tated exon 1 of foxJ1 that was predicted to include the start of the
protein. However, this sgRNA did not show any phenotype. Upon
closer inspection of the conserved Foxj1 protein sequence, we
realized that the actual protein start site is in the predicted exon 2.
When we re-designed our sgRNA to this new start site, we suc-
cessfully phenocopied the MO phenotype of decreased epidermal
cilia. Incorrect genomic sequence can also limit the use of FA to
assay for indels since it becomes difﬁcult to design speciﬁc primers
to the region of interest. Lastly, as demonstrated by our beta-ca-
tenin results, we were not able to recapitulate the early dorsal–
ventral patterning phenotype that is well-established with a
translation blocking beta-catenin MO (Heasman et al., 2000;
Khokha et al., 2005) despite using two non-overlapping CRISPRp
(data only shown for one). However, we still detect deletions using
FA, suggesting that although gene editing is taking place, there is
no phenotype likely due to presence of maternal transcript. This
serves to highlight another limitation of CRISPRp where use of a
MO might in some cases be more useful to target genes.
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phenotype or phenocopy with a second non-overlapping sgRNA is
necessary. FA can be useful to test efﬁcacy, but western blotting
remains the gold standard to assay the degree of knockdown, if
effective antibodies are available. These concerns over speciﬁcity are
no different than MOs, although the speciﬁcity of MOs have come
under scrutiny recently (Kok et al., 2015). Lastly, two studies also
suggest that injecting nuclease proteins directly, instead of gene- or
mRNA-mediated expression, potentially alleviates some off-target
effects, further arguing for use of Cas9 protein over mRNA (Gaj et al.,
2012; Izmiryan et al., 2011). Our results support the use of MOs in
Xenopus, and CRISPR phenocopy offers an alternative avenue to test
MO speciﬁcity, again especially with the use of Cas9 protein.
In conclusion, we recommend using Cas9 protein to maximize
CRISPR efﬁciency, using FA as a rapid and inexpensive tool to assay
for indels, and using CRISPRp to screen and validate the hundreds
of candidate genes being discovered from congenital malformation
patients in a rapid and efﬁcient disease model such as Xenopus.4. Materials and methods
4.1. Frog husbandry
X. tropicalis were housed and cared for in our aquatics facility
according to established protocols that were approved by our local
IACUC.
4.2. CRISPR sgRNA design
CRISPR sgRNA were designed from the v7.1 or v8 gene models
on Xenbase and ziﬁt website (http://ziﬁt.partners.org/ZiFiT/). For
the PCR method, target sites were either identiﬁed using “T7
promoter” option, which searches for 5′-GG-N(18) target se-
quence-3′, or “None” which excludes the 5′-GG. We generate the
site-speciﬁc sgRNA by ordering a single oligo that costs $10
(compare to $400 for a single MO), with the sequence 5′-CTAGC-
TAATACGACTCACTATAGG-n(18) target sequence-GTTTAGAGCTA-
GAAATAGCAAG-3′. In Fig. 1 colors correspond to red¼5 bp anchor
(CTAGC), orange¼T7 Promoter (TAATACGACTCACTATA), green-
¼site-speciﬁc n(18) target sequence, and black¼20bp compli-
mentary overhang with R-primer(GTTTAGAGCTAGAAATAGCAAG).
PCR was done using Phusion polymerase (NEB) using stock
CRISPR-R primer (Supp. Table S1) to generate the complete 100 nt
sgRNA DNA template. PCR conditions were 94 °C for 2 min, fol-
lowed by 20 cycles at 94 °C for 10 s, 45 °C for 15 s and 72 °C for
15 s, and ﬁnal extension for 5 min at 72 °C. sgRNA was transcribed
using T7 MEGAShortscript kit (Ambion) by using 8 μl of un-pur-
iﬁed PCR product in a 20 μl reaction at 37 °C for 4 h. In this study
we modiﬁed the PCR strategy previously described (Nakayama
et al., 2013) to increase RNA yield: (1) addition of a 5 bp anchor
sequence 5′ to the T7 promoter, and (2) use of Ambion's T7
MEGAshortScript kit for RNA transcription (instead of MEGAscript
kit). For example, tyrosinase sgRNA yield increased from 34 ng to
2.5 μg with the addition of the 5 bp extension, and to 45 μg when
the MEGAshortScript was used concurrently. Generally, we get 10–
50 μg of RNA per reaction. For cloning method (ccdc40, galnt11,
dnah9, tyrosinase) we used the “T7 promoter” option in the ziﬁt
program to include BsaI overhangs. Oligos 1 and 2 were combined
to a concentration of 25 mM and further diluted 1/1000x. They
were annealed by boiling at 94 °C for 2 min and then decreasing
the temperature by 0.1 °C/s to 25 °C. This was then treated with T4
PNK (NEB). The receiving vector pDR274 (Addgene ID 42250) was
linearized with BsaI and treated with CIP (NEB). Oligos were li-
gated and cloned. sgRNA was transcribed by linearizing the plas-
mid with DraI and using T7 MEGAscript kit (Ambion). sgRNAtarget sequences can be found in Supp. Table S1. We inject sgRNA
at a concentration of 400 pg/embryo except for ccdc40, which was
injected at 200 pg/embryo due to toxicity.
4.3. CRISPR Cas9 mRNA and protein
We obtained pCasX from the Cho lab (UC Irvine). Plasmid was
linearized with Asp718I and transcribed by using T7 mMessage
mMachine kit (Ambion) for 2 h at 37 °C. Cas9 Protein was ordered
from PNA-Bio (Item #CP01) and eluted to stock concentration of
1 ng/nl. We inject cas9 mRNA at a concentration of 2 ng/embryo,
Cas9 protein at a concentration of 1.5 ng/embryo.
4.4. Fragment Analysis
Tadpoles were collected at appropriate stages and lysed with
100 μl of 50 mM NaOH at 95 °C for 10 mins and neutralized with
20 μl 1 M Tris–HCl. Primers for fragment analysis were designed
with a 5′-m13 tail (5′-TCCCAGTCACGACGT-) on the Forward pri-
mer. PCR was done in 2 steps. Step 1: using 5′-m13-F primer and
R-primer; PCR conditions were 94 °C for 2 min, followed by 34
cycles at 94 °C for 10 s, 58 °C for 30 s and 72 °C for 30 s, and ﬁnal
extension for 5 min at 72 °C. Step 2: using NED, PET, VIC, or
6-FAM-m13-F primer and original R-primer and 1/50x con-
centration of PCR product from Step 1; PCR conditions were 94 °C
for 2 min, followed by 25 cycles at 94 °C for 10 s, 52 °C for 30 s and
72 °C for 30 s. Final extension was for 5 min at 72 °C. PCR products
were analyzed using fragment analysis at Yale's DNA sequencing
facility. We use the GeneMarker (SoftGenetics) software to analyze
the results. All primer sequences can be found in Supp. Table S1.
4.5. In vitro fertilization and microinjections
In vitro fertilization and microinjection were done as previously
described and protocols available on our website (http://khokha.
medicine.yale.edu). Embryos were injected at one cell stage with
0.5 or 1 ng of MO solution for Pax8, 10 ng of MO solution for Foxj1.
For CRISPR, embryos were injected at one cell stage with 2 ng of
cas9 mRNA or 1.5 ng Cas9 Protein (PNA-Bio) along with 400 pg
sgRNA for each gene, except for ccdc40, which was injected at 200
pg/embryo due to toxicity. After injections, embryos were left in 1/
9X MRþ3% Ficoll for 1 h and then transferred to 1/9X MR sup-
plemented with 50 μg/ml of gentamycin. Embryos were raised at
22–27 °C until the appropriate stage for ﬁxation or evaluating
phenotype. Pax8 translation blocking MO was obtained from
Genetools, LLC. The sequence of the MO was: 5′-
ATGCTGCTGTTGGGCATCTTCCTCC-3′. FoxJ1 translation blocking
MO was obtained from Genetools, LLC. The sequence of the MO
was: 5′-GCAGGTCAAACATTAATAAAGCCCT-3′. MO and CRISPR
were co-injected with Alexa 488 or Tetramethylrhodamine Dex-
tran dye (Life Technologies) as a lineage tracer.
4.6. Time course
Embryos were collected at 2-h interval starting from the time
of injection. For early stages, embryos were lysed using 5 μl of
50 mM NaOH at 95 °C for 5 mins and neutralized with 1 μl 1 M
Tris–HCl. Fragment analysis was performed as per protocol above.
Statistics comparing cas9 mRNA vs Protein injected embryos at
each time point was done using Fisher Exact probability test using
a 23 matrix (www.vassarstats.net/ﬁsher2x3.html).
4.7. Whole mount in situ hybridization (WMISH)
The DNA templates were in vitro transcribed with T7 High Yield
RNA Synthesis Kit (E2040S) from New England Biolabs to
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in situ hybridization was performed according to the standard
protocol with minor modiﬁcations (Khokha et al., 2002). We
stained embryos using BM purple at room temperature or 4 °C
depending on each probe. If embryos needed to be genotyped
after WMISH, ﬁxation after staining was done with 4% paraf-
ormaldehyde instead of Bouin’s ﬁxative to preserve DNA. After
bleaching and equilibration in 100% glycerol, embryos were ex-
amined and photographed.
4.8. Immunohistochemistry
For immunoﬂuorescence, embryos were ﬁxed in 4% paraf-
ormaldehyde/PBS overnight at 4 °C. Embryos were labeled by
immunoﬂuorescence as described previously (Boskovski et al.,
2013). All embryos were mounted in Pro-Long Gold (Invitrogen)
before imaging. Imaging was performed on a Zeiss Axiovert mi-
croscope equipped with Apotome optical interference imaging to
obtain optical sections. We employed the following antibodies:
anti-acetylated tubulin (Sigma, no. T-6793) (Piperno and Fuller,
1985) or mouse monoclonal anti-acetylated tubulin, clone 6-11B-1
(1:1000) (Boskovski et al., 2013). For secondary antibody we use
goat anti-mouse IgG with Alexa Flour 488 conjugate (Life tech-
nologies, Item # A-11001, 1:500 dilution).
4.9. Western blotting
Pools of 6–10 control or MO/ CRISPR injected embryos were
collected and placed in 10 ul/ embryo of 1x RIPA buffer. Embryos
were then crushed using a pestle and spun down at 14,000 RPM
for 20min. Western Blots were carried out following standard
protocols using an anti-foxj1 (AbCam, 108452, 1:250 dilution), or
anti-GAPDH (Ambion, AM4300, 1:5000 dilution) primary antibody
and an anti-mouse or anti-rabbit HRP conjugated secondary an-
tibody (Jackson Immuno Research Laboratories, 715-035-150 or
211-032-171, 1:15,000 dilution). Quantiﬁcation of changes in pro-
tein level was calculated using ImageJ software from NIH.
4.10. PCR and cloning strategy
PCR was done with Phusion High-Fidelity DNA Polymerase
(NEB) and conditions were as follows: 98 °C for 2 min, followed by
39 cycles at 98 °C for 15 s, 58 °C for 30 s and 72 °C for 30 s. Final
extension was at 72 °C for 10 min. Samples were then incubated
with Taq polymerase for 10 min at 72 °C to incorporate A over-
hangs for TOPO TA cloning (Invitrogen) and sequenced with m13R
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